Intermediate-high-risk pulmonary embolism — MRCEM SBA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Start apixaban and admit for monitored observation with reassessment for deterioration.
This is confirmed pulmonary embolism with right ventricular enlargement and myocardial injury. Tachycardia, imaging and troponin findings identify a patient at appreciable risk of deterioration, despite preserved blood pressure and perfusion. Monitored inpatient observation is therefore more appropriate than ambulatory treatment. ([nnuh.nhs.uk](https://www.nnuh.nhs.uk/publication/download/massive-acute-pulmonary-embolism-jcg0077-3/)) NICE recommends apixaban or rivaroxaban for confirmed pulmonary embolism when suitable, and advises against systemic thrombolysis in haemodynamically stable patients even when right ventricular dysfunction is present. ([nice.org.uk](https://www.nice.org.uk/guidance/ng158/chapter/Recommendations)) A provides appropriate anticoagulation but incorrectly treats this as a low-risk outpatient presentation. B mistakes right ventricular strain and raised troponin for an indication for immediate systemic thrombolysis; haemodynamic instability would change that decision. C offers therapeutic anticoagulation, but routine unmonitored observation is inadequate for this risk profile. A UK hospital guideline recommends a high-acuity setting with close observation for intermediate-high-risk pulmonary embolism. ([nnuh.nhs.uk](https://www.nnuh.nhs.uk/publication/download/massive-acute-pulmonary-embolism-jcg0077-3/)) E is inappropriate because he can receive anticoagulation; an inferior vena cava filter is considered when anticoagulation is contraindicated, rather than as its replacement here. ([nice.org.uk](https://www.nice.org.uk/guidance/ng158/chapter/Recommendations))
Reference: NICE NG158: Venous thromboembolic diseases — recommendations 1.3.8 and 1.6.3 (Updated 2 August 2023) — https://www.nice.org.uk/guidance/ng158/chapter/Recommendations NICE NG158: outpatient treatment and inferior vena caval filters (Updated 2 August 2023) — https://www.nice.org.uk/guidance/ng158/chapter/Recommendations Management of Acute Pulmonary Embolism in Adults, sections 3.6–3.8 (Approved 5 October 2023; review due 5 October 2026) — https://www.nnuh.nhs.uk/publication/download/massive-acute-pulmonary-embolism-jcg0077-3/